Arimidex Observational: Reason for and Effect of Change From Tamoxifen (ARREST)

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00246961

ARREST

D5392NL0002

Details and patient eligibility

About

The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal
• Hormone sensitive breast cancer
• Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion criteria

• Visceral metastases
• Patients with signs of progression at the moment of changing therapy
• Patients who have used other endocrine treatments for breast cancer besides tamoxifen